Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021123 | 1.00 | CA2 (0.58) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL13674348 | 0.82 | CA2 (0.62) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL4572564 | 0.82 | CA2 (0.62) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL11303240 | 0.80 | TGFBR1 (0.52) | CA2CA4SMN1; SMN2MMEFNTA | |
| SCHEMBL3631353 | 0.80 | TGFBR1 (0.52) | CA2CA4SMN1; SMN2MMEFNTA | |
| SCHEMBL4177566 | 0.80 | CA2 (0.60) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL4177568 | 0.80 | CA2 (0.60) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL28895692 | 0.80 | CA2 (0.60) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL15605900 | 0.80 | CA2 (0.60) | CA2CA4RECQLSMN1; SMN2MME | |
| SCHEMBL29238597 | 0.80 | CA2 (0.60) | CA2CA4RECQLSMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | claimed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | claimed |
| CN-102060723-B | Preparation method of cationic liposome nanoparticles of amino acid | UNIV HUNAN NORMAL | 2013-03-13 | — | — | CN | claimed |
| EP-0478729-B1 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR | NUTRASWEET CO (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0478729-A4 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR | — | 1993-06-16 | — | — | EP | claimed |
| EP-0493812-A1 | Process for preparing diketopiperazine derivatives | Ajinomoto Co., Ltd. (JP) | 1992-07-08 | — | — | EP | claimed |
| EP-0493813-A1 | 2,5-Dioxopiperazine compound and processes for preparation thereof | Ajinomoto Co., Inc. (JP) | 1992-07-08 | — | — | EP | claimed |
| EP-0478729-A1 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR. | NUTRASWEET CO (US) | 1992-04-08 | — | — | EP | claimed |
| CN-1057835-A | By the method for diketo-piperazine production aspartyl-phenylalanine methyl ester and new intermediate and derivative thereof | NUTRASWEET CO (US) | 1992-01-15 | — | — | CN | claimed |
| WO-1991014378-A1 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR | THE NUTRASWEET COMPANY (US) | 1991-10-03 | — | — | WO | claimed |
| JP-4234375-A | — | — | None | — | — | JP | disclosed |
| CN-112121231-B | Artificial blood platelet | 太阳雨林（厦门）生物医药有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| CN-112121231-A | Artificial blood platelet | 太阳雨林（厦门）生物医药有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| EP-0493813-A1 | 2,5-Dioxopiperazine compound and processes for preparation thereof | Ajinomoto Co., Inc. (JP) | 1992-07-08 | — | — | EP | disclosed |
| EP-0478729-A1 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR. | NUTRASWEET CO (US) | 1992-04-08 | — | — | EP | disclosed |
| CN-1057835-A | By the method for diketo-piperazine production aspartyl-phenylalanine methyl ester and new intermediate and derivative thereof | NUTRASWEET CO (US) | 1992-01-15 | — | — | CN | disclosed |
| WO-1991014378-A1 | PROCESS FOR MANUFACTURING ASPARTAME FROM A DIKETOPIPERAZINE AND NOVEL INTERMEDIATES AND DERIVATIVES THEREFOR | THE NUTRASWEET COMPANY (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4055663-A | Halogenated acylamino acids as fungicides | NATIONAL PATENT DEVELOPMENT CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CA2 1887/4885CA4 1168/4885RECQL 706/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CA2 1887/4885CA4 1168/4885RECQL 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.